Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This study primarily determined the safety and tolerability of escalating doses of vosaroxin
(SNS-595) in 2 dose schedules, and assessed the PK profile of vosaroxin and defined a
recommended dose regimen for Phase 2 studies. Secondarily the study assessed potential
biomarkers and antileukemic activity.